We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
Many incurable health problems are characterized by the death of cells that cannot regenerate or repair themselves upon damage or injury. Cell therapy employs stem cells to produce functional cells transplanted into patients to treat and potentially reverse the damage. The access to cell therapies has been limited by the manufacturing challenges for allogeneic transplants […]
There has been a steady rise in Attention-deficit/hyperactivity disorder (ADHD) patients during the last 20 years with adult diagnosis doubling in the last decade. With up to a 91% heritability, and the fact that ADHD can be brought on by environmental factors, this isn’t a problem that’s going to go away… it’s only going to […]
Single-cell genomics has continued to undergo enormous progress since its inception more than a decade ago. Named twice as Method of the Year by the journal Nature, it continues to evolve with this innovation delivered by ArgenTAG. ArgenTAG has developed the first truly scalable single-cell solution for long-read sequencers. The company has fundamentally changed the […]
The number of high-profile athletes suffering from neurodegenerative disease, the result of repeated concussions during their sports career, has raised awareness of the problems associated with recurrent concussions and the resulting brain trauma. Concussions in athletes are very common. About 3.8 million concussions occur each year in the U.S. from sports-related injuries. The CDC estimates […]
Preeclampsia, a potentially fatal pregnancy condition characterized by high blood pressure and organ damage, is the second leading cause of maternal mortality worldwide, despite the condition being straightforward to treat when detected early. The current diagnosis of preeclampsia using blood pressure and proteinuria is inaccurate and requires routine clinical visits, making it inaccessible to many. […]
Neurological disorders, like Alzheimer’s, can be challenging to diagnose, especially earlier in the disease progression when symptoms are subtle. Alzheimer’s is both under-diagnosed and misdiagnosed, resulting in delayed diagnosis and treatment on average by 2-3 years after symptom onset and only in the latter stages of the disease once it has taken hold. Based on […]
In the field of liquid biopsy, the abundance of new technologies are mere screening tests. They can’t monitor patients’ progression and drive clinical decisions. The real money is in monitoring disease patients, for years. Atomic Force Microscopy scans the surface of cells at such high resolution that it can not only discriminate cancer cells from […]
Potassium controls every single heartbeat you have, but it’s the kidneys that control your potassium levels. You could say the kidneys are the gatekeeper to your heart. Kidney care is going through dramatic market disruption. Home dialysis is displacing clinics. And patient care management companies are siphoning off patients. Nevertheless, these patients are still ending […]
In the last few years, aptamers linked to CRISPR have brought programmable logic to drug design. However, the logic is primitive – once turned on, CRISPR remains on. Wayfinder is working on RNA-biosensors so that drugs can continuously sense their microenvironment, and turn modalities like CRISPR both on and off in response to what they […]
Modern lifestyles are hard on our livers and kidneys, the organs that filter and break down metabolic waste products. But people don’t want to take drugs – they want to get healthy. Unlocked Labs unleashes the power of the microbiome to help out. Unlocked is a consumer probiotic company that unlocks silent genes – regaining […]